GW Pharma announces plan to commercialize nabiximols in the U.S.

GW Pharmaceuticals (NASDAQ:GWPH) announces strategy for bringing its pipeline product nabiximols to the U.S. market.

The company plans to commence a Phase 3 clinical program, including, MS Spasticity Clinical program, Spinal Cord Injury spasticity program and Post Traumatic Stress Disorder program which will provide multiple opportunities for an NDA submission, as early as 2021.

The company will host a webcast today, from 10:00am to 12:00pm EDT to provide insight into the U.S. Phase 3 clinical program and commercial opportunity for nabiximols.

Nabiximols is a botanical medicine formulated from extracts of the cannabis plant. The product is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis.

https://seekingalpha.com/news/3587242-gw-pharma-announces-plan-to-commercialize-nabiximols-in-u-s